GlassScriptPhysician profile
James B Wilhite
NPI 1043329808
$2,489.70
in general payments reported to CMS, 2019-2025
32 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $329 · 2021: $741 · 2022: $258 · 2023: $307 · 2024: $79.52 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.18 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.42 | 2019-2025 | Qulipta, Vraylar |
| Amgen INC. | $234.79 | 2019-2025 | Otezla, Repatha, Prolia |
| Amarin Pharma, INC. | $197.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $161.82 | 2020-2022 | |
| Glaxosmithkline, LLC. | $140.95 | 2020-2023 | Trelegy Ellipta |
| Urovant Sciences INC | $125.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $119.20 | 2019-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $113.43 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $108.95 | 2019 | |
| Alcon Vision LLC | $102.60 | 2021 | |
| Pfizer INC. | $95.82 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.75 | 2023 | Xifaxan |
| Biogen, INC. | $81.91 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $70.84 | 2019-2023 | Tecnis Iol |
| Allergan, INC. | $69.38 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $43.68 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $36.93 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.19 | 2019 | |
| Novo Nordisk INC | $28.81 | 2020-2022 | |
| Esperion Therapeutics, INC. | $27.49 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.05 | 2019 | |
| Glaukos Corporation | $24.23 | 2025 | Photrexa Viscous and Photrexa |
| Lilly USA, LLC | $24.08 | 2019 | |
| Genentech USA, INC. | $22.78 | 2020 | |
| Melinta Therapeutics, LLC | $20.00 | 2019 | |
| Astellas Pharma US INC | $17.79 | 2020 | |
| Mylan Specialty L.P. | $17.57 | 2019 | |
| Oyster Point Pharma, INC. | $17.44 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.78 | 2021 | |
| Rxsight INC | $16.20 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Takeda Pharmaceuticals U.S.A., INC. | $15.36 | 2022 | |
| Biodelivery Sciences International, INC. | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilhite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.